Summary:
Insilico Medicine has launched a new research initiative called “Longevity Vaccines,” applying generative artificial intelligence and programmable circular RNA (cmRNA) delivered via lipid nanoparticles to instruct a patient’s own immune cells to eliminate senescent, fibrotic, and autoreactive cells.
Rather than managing downstream disease pathology, the self-limiting in vivo cell therapy aims to rejuvenate aging tissues, starting with the immune system, before chronic neurodegenerative and age-related decline takes hold.
Key Facts:
- In Vivo T-Cell Arming: The platform delivers transient genetic instructions via circular mRNA (cmRNA) encapsulated in targeted lipid nanoparticles (LNPs), enabling the body’s own T cells to recognize and clear early driver cells of aging without permanent genetic alteration.
- AI-Driven Target Discovery: Candidates are identified and prioritized using Pharma.AI foundation models and the “Virtual Aging Cell,” which map the earliest deviations in cell trajectories to find highly specific surface antigens.
- Primary Focus on Immune Rejuvenation: The first target indication addresses immunosenescence by removing accumulated senescent lymphocytes, with subsequent pipelines planned for metabolic dysfunction, fibrosis, and chronic autoimmune degeneration.
Source: Insilico Medicine
Aging remains the leading driver of human chronic disease, including cognitive impairment, neurodegeneration, metabolic decline, and systemic inflammation. At the cellular level, these conditions are frequently initiated and fueled by small, aberrant cell populations: senescent cells releasing destructive inflammatory cocktails (the senescence-associated secretory phenotype, or SASP), rogue autoreactive lymphocytes, and activated fibroblasts driving tissue stiffness.
Current therapeutics primarily intervene after extensive tissue damage has accumulated. To disrupt this paradigm, clinical-stage generative AI biotechnology company Insilico Medicine announced its “Longevity Vaccines” research program. The program aims to deploy single-administration, self-limiting in vivo therapies that mobilize the body’s own adaptive immune system to hunt down and clear these culprit cells at their onset.
“We built Insilico to treat aging and disease together, and to prove that AI can design medicines that deliver real patient impact,” said Alex Zhavoronkov, PhD, Founder and co-CEO of Insilico Medicine. “Longevity Vaccines initiative extends that same rigor to preventive medicine—delivering programmable, single-dose therapies that clear the root-cause cells of age-related disease, starting with the immune system itself.”
Programmable Circular mRNA in Targeted Nanoparticles
Traditional cell therapies like ex-vivo CAR T cells require complex, costly laboratory engineering outside the patient’s body and risk prolonged immune overactivation. In contrast, Insilico’s platform relies on an in vivo delivery chassis:
- Circular mRNA (cmRNA): Closed-loop RNA structures that resist enzymatic degradation, providing robust yet ultimately transient (self-limiting) protein expression inside recipient immune cells.
- Targeted Lipid Nanoparticles (LNPs): Selective lipid vehicles designed via generative chemistry to deliver the cmRNA cargo specifically into endogenous T cells inside the body.
Once internalized, the genetic instructions temporarily equip host T cells with synthetic receptors targeting markers on diseased cells. Because the mRNA naturally degrades over time, the cell-clearing activity remains transient, minimizing the risk of prolonged immune suppression or off-target exhaustion.
Pinpointing the Earliest Surface Antigens via Pharma.AI
In preventive intervention, selecting molecular targets requires an exceptionally stringent safety threshold: markers must distinguish diseased or senescent cells from healthy somatic tissues across the entire human body.
To solve this, Insilico integrates its proprietary end-to-end Pharma.AI pipeline:
- PandaOmics & Virtual Aging Cell: Foundation models that analyze multi-omics data conditioned on chronological and biological age, mapping the exact points where cells first deviate from health into dysfunction.
- Chemistry42 & Generative Biologics: De novo molecular design engines that generate tailored binders and engineer ionizable lipids for organ- and cell-specific delivery.
- Whole-Body Surface Atlas: Comprehensive computational screening to verify that candidate targets are absent from vital, healthy organs.
Target candidates are then routed through automated robotic wet labs, where continuous functional assay loops refine target rankings and molecular constructs.
Reversing Immunosenescence and Future Applications
The maiden application for the Longevity Vaccines platform will focus on immunosenescence, the progressive deterioration of the immune system with age. As individuals grow older, exhausted and senescent lymphocytes accumulate, causing chronic systemic inflammation (“inflammaging”), decreasing immune surveillance against malignancies, and reducing vaccine responsiveness.
Systemic inflammation driven by an aging immune system is also recognized as a key accelerator of neuroinflammation and neurodegenerative pathology in the brain. By resetting the immune compartment, researchers hope to restore baseline tissue homeostasis throughout the body. Beyond immune rejuvenation, the company is evaluating the same chassis to target cellular culprits in metabolic dysfunction and fibrotic disorders.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this AI and Longevity Research:
- Media Contact: Joy Hu
- Source: InSilico Medicine
- Image Credit: Image generated for Neuroscience News
